Baylor University Medical Center
Infectious Disease fellowship · Dallas, TX · Baylor University Medical Center programs · Program website
Internal Medicine residency here · Other fellowships: Cardiovascular Disease · Gastroenterology · Pulmonary and Critical Care · Hematology and Oncology · Nephrology
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Baylor University Medical Center's research in infectious disease, which the program shares with other departments and affiliated hospitals.
Infectious Disease at Baylor University Medical Centershared by every program there, not this program's own
Institution-level: all infectious disease publications from Baylor University Medical Center and affiliated institutions, since 2022. Updated 2026-11-08; refreshed daily.
Works per year · * 2026 so far
Infectious Disease research topics at Baylor University Medical Center
Papers in the window; each links to the list on OpenAlex.
Most cited at Baylor University Medical Center since 2024
All infectious disease papers there on OpenAlex
- Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyOnyema Eberechukwu Ogbuagu et al. · The Lancet Infectious Diseases · 2025 · PubMed · cited 16
- Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025Ruth Link‐Gelles et al. · MMWR Morbidity and Mortality Weekly Report · 2025 · PubMed · cited 92
- Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant EraEssy Mozaffari et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 19
- Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19Essy Mozaffari et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 15
- At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methodsMunib Mesinovic et al. · Scientific Reports · 2024 · PubMed · cited 14
- Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical TrialMeghan E. Sise et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 22
- Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental OxygenEssy Mozaffari et al. · Open Forum Infectious Diseases · 2024 · PubMed · cited 20
- No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog et al. · Viruses · 2024 · PubMed · cited 13
- Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024Jennifer DeCuir et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · PubMed · cited 71
- Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19Neil R. Aggarwal et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 15
Add to your program's websitea badge, your paper list, a feed
For program directors and coordinators. Both update with the site and need no account.
<a href="https://openprograms.org/programs/baylor-university-medical-center-id"><img src="https://openprograms.org/programs/baylor-university-medical-center-id/badge.svg" alt="Baylor University Medical Center Infectious Disease fellowship on OpenPrograms" height="20"></a>Something wrong or missing on this page? Use the correction form below; changes show up in both.